Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
FGFR2 Gene Mutation: early-phase trial registry
1 of 2 indexed FGFR2 Gene Mutation trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
FGFR2 Gene Mutation: 2 US clinical trials tracked, 1 recruiting.
FGFR2 Gene Mutation is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Elevar Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition fgfr2-gene-mutation
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
FGFR2 Gene Mutation lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for FGFR2 Gene Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
FGFR2 Gene Mutation is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Mehmet Akce
NCT06728410
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Elevar Therapeutics
NCT04526106
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on FGFR2 Gene Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on FGFR2 Gene Mutation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this FGFR2 Gene Mutation page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 FGFR2 Gene Mutation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Elevar Therapeutics sponsors the most FGFR2 Gene Mutation trials on record, review their full trial history before evaluating a specific study. See Elevar Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This FGFR2 Gene Mutation condition card totals 2 registered trials; most-linked intervention RLY-4008; top US site state Alabama. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.